suramin has been researched along with Colorectal Neoplasms in 6 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
| Excerpt | Relevance | Reference |
|---|---|---|
| "These results indicate that suramin is inactive in patients with metastatic colorectal cancer pretreated with fluoropyrimidines." | 9.08 | Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study. ( Brunetti, I; Cianci, C; Conte, PF; Danesi, R; Del Tacca, M; Falcone, A; Pfanner, E, 1995) |
| "Suramin is a novel hepsin inhibitor that reduces its protumorigenic and prothrombotic effects in colorectal cancer cells." | 8.31 | Suramin, a drug for the treatment of trypanosomiasis, reduces the prothrombotic and metastatic phenotypes of colorectal cancer cells by inhibiting hepsin. ( Carmona-Bayonas, A; Espín, S; García-Molina, F; Lozano, ML; Martínez-Martínez, I; Mulero, V; Nieto, A; Pardo-Sánchez, I; Peña-García, J; Peñas-Martínez, J; Pérez-Sánchez, H; Ricote, G; Rodenas, MC; Vicente, V; Zaragoza-Huesca, D, 2023) |
| "Suramin, a polysulphonated naphthylurea proven to be an effective anticancer agent against selected tumours, and alpha 2A-interferon (alpha 2A-IFN) were investigated for their combined effects on HCT-8, HCT-15, CL-D, SW-480 and SW-620 human colorectal adenocarcinoma cell lines." | 7.69 | Synergistic antiproliferative activity of suramin and alpha 2A-interferon against human colorectal adenocarcinoma cell lines: in vitro studies. ( Andreuccetti, M; Cianci, C; Conte, PF; Danesi, R; Del Tacca, M; Falcone, A; Malvaldi, G; Pfanner, E; Pieracci, D; Zaccaro, L, 1994) |
| "These results indicate that suramin is inactive in patients with metastatic colorectal cancer pretreated with fluoropyrimidines." | 5.08 | Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study. ( Brunetti, I; Cianci, C; Conte, PF; Danesi, R; Del Tacca, M; Falcone, A; Pfanner, E, 1995) |
| "Suramin is a novel hepsin inhibitor that reduces its protumorigenic and prothrombotic effects in colorectal cancer cells." | 4.31 | Suramin, a drug for the treatment of trypanosomiasis, reduces the prothrombotic and metastatic phenotypes of colorectal cancer cells by inhibiting hepsin. ( Carmona-Bayonas, A; Espín, S; García-Molina, F; Lozano, ML; Martínez-Martínez, I; Mulero, V; Nieto, A; Pardo-Sánchez, I; Peña-García, J; Peñas-Martínez, J; Pérez-Sánchez, H; Ricote, G; Rodenas, MC; Vicente, V; Zaragoza-Huesca, D, 2023) |
| "Suramin, a polysulphonated naphthylurea proven to be an effective anticancer agent against selected tumours, and alpha 2A-interferon (alpha 2A-IFN) were investigated for their combined effects on HCT-8, HCT-15, CL-D, SW-480 and SW-620 human colorectal adenocarcinoma cell lines." | 3.69 | Synergistic antiproliferative activity of suramin and alpha 2A-interferon against human colorectal adenocarcinoma cell lines: in vitro studies. ( Andreuccetti, M; Cianci, C; Conte, PF; Danesi, R; Del Tacca, M; Falcone, A; Malvaldi, G; Pfanner, E; Pieracci, D; Zaccaro, L, 1994) |
| "Corneal neovascularization was induced in three groups of nine white New Zealand rabbits, applying a filter paper disk soaked in 1 M NaOH on the central cornea (Ormerod et al." | 1.37 | Suramab, a novel antiangiogenic agent, reduces tumor growth and corneal neovascularization. ( Croxatto, JO; Gallo, JE; Lopez, ES; Mazzolini, G; Rizzo, MM, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Zaragoza-Huesca, D | 1 |
| Rodenas, MC | 1 |
| Peñas-Martínez, J | 1 |
| Pardo-Sánchez, I | 1 |
| Peña-García, J | 1 |
| Espín, S | 1 |
| Ricote, G | 1 |
| Nieto, A | 1 |
| García-Molina, F | 1 |
| Vicente, V | 1 |
| Lozano, ML | 1 |
| Carmona-Bayonas, A | 1 |
| Mulero, V | 1 |
| Pérez-Sánchez, H | 1 |
| Martínez-Martínez, I | 1 |
| Lopez, ES | 1 |
| Rizzo, MM | 1 |
| Croxatto, JO | 1 |
| Mazzolini, G | 1 |
| Gallo, JE | 1 |
| Guo, K | 1 |
| Li, J | 1 |
| Wang, H | 1 |
| Osato, M | 1 |
| Tang, JP | 1 |
| Quah, SY | 1 |
| Gan, BQ | 1 |
| Zeng, Q | 1 |
| Allen, PD | 1 |
| Johnston, DH | 1 |
| Macey, MG | 1 |
| Williams, NS | 1 |
| Newland, AC | 1 |
| Falcone, A | 2 |
| Pfanner, E | 2 |
| Cianci, C | 2 |
| Danesi, R | 2 |
| Brunetti, I | 1 |
| Del Tacca, M | 2 |
| Conte, PF | 2 |
| Zaccaro, L | 1 |
| Pieracci, D | 1 |
| Andreuccetti, M | 1 |
| Malvaldi, G | 1 |
1 trial available for suramin and Colorectal Neoplasms
| Article | Year |
|---|---|
Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study.
Topics: Adult; Aged; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Humans; Male; Middle Aged; Neo | 1995 |
5 other studies available for suramin and Colorectal Neoplasms
| Article | Year |
|---|---|
Suramin, a drug for the treatment of trypanosomiasis, reduces the prothrombotic and metastatic phenotypes of colorectal cancer cells by inhibiting hepsin.
Topics: Animals; Caco-2 Cells; Colorectal Neoplasms; Humans; Molecular Docking Simulation; Phenotype; Surami | 2023 |
Suramab, a novel antiangiogenic agent, reduces tumor growth and corneal neovascularization.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineo | 2011 |
PRL-3 initiates tumor angiogenesis by recruiting endothelial cells in vitro and in vivo.
Topics: Animals; Blood Vessels; Cell Movement; CHO Cells; Coculture Techniques; Colorectal Neoplasms; Cricet | 2006 |
Colorectal cell line suppression of lymphokine activated killer cell generation is reversed by suramin.
Topics: Antigens, CD; Antigens, Differentiation, B-Lymphocyte; Antigens, Differentiation, T-Lymphocyte; CD56 | 1995 |
Synergistic antiproliferative activity of suramin and alpha 2A-interferon against human colorectal adenocarcinoma cell lines: in vitro studies.
Topics: Adenocarcinoma; Cell Division; Cell Survival; Colorectal Neoplasms; Dose-Response Relationship, Drug | 1994 |